BioMarin Pharmaceutical (BMRN) Q3 2026 earnings — TrendMatrix coverage
Reported
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. How we score · Full disclosure · Editorial policy
Key numbers
- Adjusted EPS
- $0.23
- Estimate
- -$0.11
- Surprise
- +304.8%
- Score at report (before → after)
- 5.4 → 5.6/10
Revenue for this quarter isn’t shown: the reported figure hasn’t cleared TrendMatrix’s freshness and sanity checks yet, and consensus revenue isn’t tracked. EPS above is the available figure.
How the report landed
BioMarin Pharmaceutical (BMRN) beat the -$0.11 estimate with adjusted EPS of $0.23 — a large 304.8% upside surprise. TrendMatrix's engine moved from Hold (5.4/10) to Sell at 5.6/10 after the report.
Coverage in the report window
- BioMarin Pharmaceutical Lowers FY2026 Adj EPS Guidance from $4.90-$5.10 to $2.80-$3.10 vs $3.32 Est; Lowers FY2026 Sales — benzinga, 2026-11-02
Where TrendMatrix's rating stands now
TrendMatrix currently rates BMRN Sell at 5.6/10.
2 of the last 4 quarters beat the estimate; this quarter's +304.8% surprise compares with a +73.9% four-quarter average.
What supports the rating
- Sector modifier (Healthcare): +0.5
- Analyst upside: 43%
What argues against it
- Concentration risk — Customer: Sanofi
- Concentration risk — Supplier: sole source raw material suppliers
- Consecutive earnings misses (2)
This section and the ones below it reflect TrendMatrix’s latest engine read — they update after the report date and are not frozen to it.
The levels TrendMatrix's engine tracks
- Current price
- $57.44
- Price target
- $82.40
- Stop
- $54.04
- Upside to target
- +43.5%
- Reward-to-risk
- 7.0:1
The stock trades at 155.2× trailing but 9.0× forward earnings — consensus estimates already build in a substantial earnings recovery.
Model outputs from TrendMatrix’s engine as of 2026-11-03 — shown for context, not personalized investment advice.
BMRN at TrendMatrix's latest read
Healthcare earnings trade on pipeline and payer dynamics as much as the quarter itself; a beat or miss is weighed against trial and reimbursement news.
- Industry
- Biotechnology
- Market cap
- $11.12B
- P/E (fwd)
- 9.0
- P/E (ttm)
- 155.2
- 52-week range
- $49.26–$70.98
- Off 52-week high
- 19.1%
- RSI (14)
- 62
- Volume vs avg
- 1.27×
- Score today
- 5.6/10